23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Tarsus Pharmaceuticals, Inc. › 2025-2026

Tarsus Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Tarsus Pharmaceuticals, Inc.’s Form 8-K, filed June 29, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 292Asset managers, any item
  • 1,852Fund votes
  • June 25, 2026Meeting date

Results at a glance

Meeting of June 25, 2026: 6 items on Tarsus Pharmaceuticals, Inc.’s Form 8-K, filed June 29, 2026: 4 elected · 2 approved.

Dissent

Significant dissent: 1 director (23.1% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Tang Capital (13F, 3.9%, as of September 30, 2026)

Explore Tarsus Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Tarsus Pharmaceuticals, Inc.

These tallies are Tarsus Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 29, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Tarsus Pharmaceuticals, Inc. — official shareholder meeting results, meeting held June 25, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Wendy Yarno, MBA 34,398,690---- 374,9563,463,568 99%Elected—
Elect Director: Andrew Goldberg, M.D. 26,733,789---- 8,039,8573,463,568 77%Elected—
Elect Director: Scott Morrison 34,225,471---- 548,1753,463,568 98%Elected—
Elect Director: David E.I. Pyott, MBA 33,612,963---- 1,160,6833,463,568 97%Elected—
2. Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory, non-binding basis, the compensation paid to the Company's named executive officers as disclosed in the Proxy Statement. The 34,486,767238,01448,865 --3,463,568 99.3%Approved—
3. Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm 38,219,5213,65114,042 ---- 99.9%Approved—

Source: Tarsus Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 29, 2026 — read the filing on EDGAR.

How asset managers voted at the Tarsus Pharmaceuticals, Inc. 2025-2026 meeting

292 asset managers disclosed a vote on at least one Tarsus Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Andrew Goldberg, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD
FOR: 26,733,789WITHHELD: 8,039,857
Details: description as filed, official tally, votes by 87 asset managers

Description as filed by funds: To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: Andrew Goldberg

Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Andrew Goldberg, M.D.”): 26,733,789 for, 8,039,857 withheld, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Board of Directors Election Results The following nominees were elected to serve as Class III directors for a term that will continue until the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified.”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 87 asset managers below reported 9,333,289 for, 2,236,585 withheld, 17 abstained.

FORWITHHOLD
FOR: 9,333,289ABSTAIN: 17WITHHOLD: 2,236,585
Largest asset managers voting on “To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective” at Tarsus Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,084,4080 1723,250For
BlackRock1,588,5790 00For
Fidelity1,286,6080 018,000For
Prudential/PGIM667,3670 098,272Mixed
JANUS INVESTMENT FUND738,2210 00For
Lord Abbett504,3660 00For
Legg Mason443,2090 00For
Invesco441,4220 00For
Charles Schwab329,5200 00For
Waddell & Reed00 0273,131Withhold
TIAA267,6080 00For
MFS00 0261,461Withhold
Loomis Sayles00 0222,303Withhold
T. Rowe Price180,4010 00For
DRIEHAUS MUTUAL FUNDS00 0174,580Withhold
Putnam147,3180 00For
Allspring00 0120,498Withhold
Equitable91,1480 025,540Mixed
First Trust00 0110,377Withhold
Delaware/Macquarie00 0100,000Withhold
State Street97,3050 065For
Bridge Builder Trust34,3840 055,134Mixed
MoA Funds Corp00 067,022Withhold
QUANTITATIVE MASTER SERIES LLC64,8850 00For
Franklin Custodian Funds00 059,777Withhold

Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).

Elect Director: David E.I. Pyott, MBA

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 33,612,963WITHHELD: 1,160,683
Details: description as filed, official tally, votes by 87 asset managers

Description as filed by funds: To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: David E.I. Pyott

Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David E.I. Pyott, MBA”): 33,612,963 for, 1,160,683 withheld, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Board of Directors Election Results The following nominees were elected to serve as Class III directors for a term that will continue until the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 87 asset managers below reported 10,693,047 for, 876,840 withheld, 3 abstained.

FOR
FOR: 10,693,047ABSTAIN: 3WITHHOLD: 876,840
Largest asset managers voting on “To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective” at Tarsus Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,107,6720 30For
BlackRock1,588,5790 00For
Fidelity1,304,6080 00For
Prudential/PGIM765,6390 00For
JANUS INVESTMENT FUND738,2210 00For
Lord Abbett504,3660 00For
Legg Mason443,2090 00For
Invesco441,4220 00For
Charles Schwab329,5200 00For
Waddell & Reed00 0273,131Withhold
TIAA267,6080 00For
MFS261,4610 00For
Loomis Sayles00 0222,303Withhold
T. Rowe Price180,4010 00For
DRIEHAUS MUTUAL FUNDS174,5800 00For
Putnam10,1170 0137,201Mixed
Allspring120,4980 00For
Equitable116,6880 00For
First Trust110,3770 00For
Delaware/Macquarie00 0100,000Withhold
State Street97,3700 00For
Bridge Builder Trust89,5180 00For
MoA Funds Corp67,0220 00For
QUANTITATIVE MASTER SERIES LLC64,8850 00For
Franklin Custodian Funds59,7770 00For

Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).

Elect Director: Scott Morrison

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 34,225,471WITHHELD: 548,175
Details: description as filed, official tally, votes by 87 asset managers

Description as filed by funds: To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: Scott Morrison

Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Scott Morrison”): 34,225,471 for, 548,175 withheld, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Board of Directors Election Results The following nominees were elected to serve as Class III directors for a term that will continue until the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 87 asset managers below reported 11,557,159 for, 12,730 withheld, 1 abstained.

FOR
FOR: 11,557,159ABSTAIN: 1WITHHOLD: 12,730
Largest asset managers voting on “To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective” at Tarsus Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,105,8240 11,850For
BlackRock1,588,5790 00For
Fidelity1,304,6080 00For
Prudential/PGIM765,6390 00For
JANUS INVESTMENT FUND738,2210 00For
Lord Abbett504,3660 00For
Legg Mason443,2090 00For
Invesco441,4220 00For
Charles Schwab329,5200 00For
Waddell & Reed273,1310 00For
TIAA267,6080 00For
MFS261,4610 00For
Loomis Sayles222,3030 00For
T. Rowe Price180,4010 00For
DRIEHAUS MUTUAL FUNDS174,5800 00For
Putnam147,3180 00For
Allspring120,4980 00For
Equitable116,6880 00For
First Trust110,3770 00For
Delaware/Macquarie100,0000 00For
State Street97,3700 00For
Bridge Builder Trust89,5180 00For
MoA Funds Corp67,0220 00For
QUANTITATIVE MASTER SERIES LLC64,8850 00For
Franklin Custodian Funds59,7770 00For

Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).

Elect Director: Wendy Yarno, MBA

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 34,398,690WITHHELD: 374,956
Details: description as filed, official tally, votes by 87 asset managers

Description as filed by funds: To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: Wendy Yarno

Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Wendy Yarno, MBA”): 34,398,690 for, 374,956 withheld, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Board of Directors Election Results The following nominees were elected to serve as Class III directors for a term that will continue until the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 87 asset managers below reported 11,566,635 for, 3,254 withheld, 1 abstained.

FOR
FOR: 11,566,635ABSTAIN: 1WITHHOLD: 3,254
Largest asset managers voting on “To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective” at Tarsus Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,107,6740 10For
BlackRock1,588,5790 00For
Fidelity1,304,6080 00For
Prudential/PGIM765,6390 00For
JANUS INVESTMENT FUND738,2210 00For
Lord Abbett504,3660 00For
Legg Mason443,2090 00For
Invesco441,4220 00For
Charles Schwab329,5200 00For
Waddell & Reed273,1310 00For
TIAA267,6080 00For
MFS261,4610 00For
Loomis Sayles222,3030 00For
T. Rowe Price180,4010 00For
DRIEHAUS MUTUAL FUNDS174,5800 00For
Putnam147,3180 00For
Allspring120,4980 00For
Equitable116,6880 00For
First Trust110,3770 00For
Delaware/Macquarie100,0000 00For
State Street97,3700 00For
Bridge Builder Trust89,5180 00For
MoA Funds Corp67,0220 00For
QUANTITATIVE MASTER SERIES LLC64,8850 00For
Franklin Custodian Funds59,7770 00For

Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).

2. Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

99.3% Approved · of votes cast

FOR 99.3%
FOR: 34,486,767AGAINST: 238,014
Details: description as filed, official tally, votes by 292 asset managers

Description as filed by funds: To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation.

Tarsus Pharmaceuticals, Inc.’s own tally for this item (“2. Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory, non-binding basis, the compensation paid to the Company's named executive officers as disclosed in the Proxy S”): 34,486,767 for, 238,014 against — passed, per its Form 8-K filed June 29, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory, non-binding basis, the compensation paid to the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 87 asset managers voting on “To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation.” at Tarsus Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,107,6740 00For
BlackRock1,588,5790 00For
Fidelity1,304,6080 00For
Prudential/PGIM765,6390 00For
JANUS INVESTMENT FUND738,2210 00For
Lord Abbett504,3660 00For
Legg Mason443,2090 00For
Invesco441,4220 00For
Charles Schwab329,5200 00For
Waddell & Reed273,1310 00For
TIAA267,6080 00For
MFS261,4610 00For
Loomis Sayles222,3030 00For
T. Rowe Price180,4010 00For
DRIEHAUS MUTUAL FUNDS174,5800 00For
Putnam147,3180 00For
Allspring120,4980 00For
Equitable116,6880 00For
First Trust110,3770 00For
RBB FUND, INC.100,9810 00For
Delaware/Macquarie100,0000 00For
State Street97,3700 00For
Bridge Builder Trust89,5180 00For
MoA Funds Corp67,0220 00For
QUANTITATIVE MASTER SERIES LLC64,8850 00For

Fund voting reports, all 87 managers: 11,609,988 for, 3,272 against, 33,254 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 233 asset managers voting on “To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation.” at Tarsus Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Janus Henderson4,604,7070 00For
Deep Track Capital, LP3,557,6780 00For
RTW INVESTMENTS, LP3,346,0250 00For
Paradigm Biocapital Advisors LP2,002,0800 00For
Invesco1,666,0030 00For
JENNISON ASSOCIATES LLC1,399,0980 00For
BlackRock1,374,163195 00For
GEODE CAPITAL MANAGEMENT, LLC1,025,7210 00For
State Street881,9391,255 00For
Frazier Life Sciences Management, L.P.728,6440 00For
Fidelity703,8220 00For
LORD, ABBETT & CO. LLC685,2160 00For
Clearbridge Investments, LLC543,9610 00For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST499,3060 00For
DRIEHAUS CAPITAL MANAGEMENT LLC493,3200 00For
Loomis Sayles393,9940 00For
TimesSquare Capital Management, LLC356,3400 00For
Charles Schwab329,6030 00For
Northern Trust324,8950 00For
Vanguard318,8380 00For
MASSACHUSETTS FINANCIAL SERVICES CO /MA/316,5950 00For
T. Rowe Price308,6870 00For
Ensign Peak Advisors, Inc307,5040 00For
Nuveen283,2460 00For
Artisan264,1970 00For

Institutional-manager reports, all 233 managers: 30,687,848 for, 124,712 against, 24,951 abstained, 180 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm

Official resultAUDIT-RELATEDReported outcome: Approved

99.9% Approved · of votes cast

FOR 99.9%
FOR: 38,219,521AGAINST: 3,651

Prior year: 99.6% for (June 12, 2025 meeting) ▲ 0.3 pts

Details: description as filed, official tally, votes by 87 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Tarsus Pharmaceuticals, Inc.’s own tally for this item (“3. Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm”): 38,219,521 for, 3,651 against — passed, per its Form 8-K filed June 29, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm The Company's stockholders approved the ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 87 asset managers below reported 11,566,636 for, 3,254 abstained.

FOR
FOR: 11,566,636ABSTAIN: 3,254
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at Tarsus Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,107,6750 00For
BlackRock1,588,5790 00For
Fidelity1,304,6080 00For
Prudential/PGIM765,6390 00For
JANUS INVESTMENT FUND738,2210 00For
Lord Abbett504,3660 00For
Legg Mason443,2090 00For
Invesco441,4220 00For
Charles Schwab329,5200 00For
Waddell & Reed273,1310 00For
TIAA267,6080 00For
MFS261,4610 00For
Loomis Sayles222,3030 00For
T. Rowe Price180,4010 00For
DRIEHAUS MUTUAL FUNDS174,5800 00For
Putnam147,3180 00For
Allspring120,4980 00For
Equitable116,6880 00For
First Trust110,3770 00For
Delaware/Macquarie100,0000 00For
State Street97,3700 00For
Bridge Builder Trust89,5180 00For
MoA Funds Corp67,0220 00For
QUANTITATIVE MASTER SERIES LLC64,8850 00For
Franklin Custodian Funds59,7770 00For

Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).

Largest Tarsus Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 43,021,312 shares outstanding at the time of that meeting.

Fund voting reports: top Tarsus Pharmaceuticals, Inc. shareholders by shares voted on “To hold an advisory vote to approve, on a non-binding basis, our named executive officer…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 4.90%
2BlackRock 3.69%
3Fidelity 3.03%
4Prudential/PGIM 1.78%
5JANUS INVESTMENT FUND 1.72%
6Lord Abbett 1.17%
7Legg Mason 1.03%
8Invesco 1.03%
9Charles Schwab 0.77%
10Waddell & Reed 0.63%
Institutional-manager reports: top Tarsus Pharmaceuticals, Inc. shareholders by shares voted on “To hold an advisory vote to approve, on a non-binding basis, our named executive officer…”, 2025-2026
#Asset manager % of shares outstanding
1Janus Henderson 10.70%
2Deep Track Capital, LP 8.27%
3RTW INVESTMENTS, LP 7.78%
4Paradigm Biocapital Advisors LP 4.65%
5Invesco 3.87%
6JENNISON ASSOCIATES LLC 3.25%
7BlackRock 3.19%
8GEODE CAPITAL MANAGEMENT, LLC 2.38%
9State Street 2.05%
10Frazier Life Sciences Management, L.P. 1.69%

Reported Tarsus Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Tarsus Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Deep Track Capital, LP3,600,000 8.37%Schedule 13G, filed May 15, 2026
BlackRock3,552,612 8.26%Form 13F, quarter ended March 31, 2026
RTW Investments, LP3,424,180 7.96%Proxy statement (DEF 14A), proxy filed April 28, 2026
Paradigm BioCapital Advisors LP2,440,445 5.67%Proxy statement (DEF 14A), proxy filed April 28, 2026
Vanguard Group2,399,560 5.58%Form 13F, quarter ended March 31, 2026
JANUS HENDERSON GROUP PLC2,240,963 5.21%Schedule 13G, filed May 15, 2026
Bobak Azamian2,221,102 5.16%Proxy statement (DEF 14A), proxy filed April 28, 2026
Morgan Stanley2,040,742 4.74%Form 13F, quarter ended March 31, 2026
PRUDENTIAL FINANCIAL INC1,836,321 4.27%Schedule 13G, filed May 8, 2026
Jennison Associates LLC1,712,124 3.98%Schedule 13G, filed May 6, 2026

Percentages above are of 43,021,312 shares outstanding, as reported by Tarsus Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Tarsus Pharmaceuticals, Inc.'s shareholder meeting held June 25, 2026, in the 2025-2026 proxy season, 292 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,852 separate fund positions. On the most widely held item on that ballot — To hold an advisory vote to approve, on a non-binding basis, our named executive officer… — Tarsus Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 99.3% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Tarsus Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 29, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Tarsus Pharmaceuticals, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Tarsus Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Tarsus Pharmaceuticals (TARS) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/tarsus-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.